U.S. Office — Brooklyn, NY · Mon–Fri 9:00–18:00 ET
Direct: +1 (347) 567-0781 · Email: info@sucotondusa.com
ProductsAboutCertificationsVerify FactoryBlogContact
Custom Development · Private Label

Turn a glutathione gummy concept into a testable commercial specification.

Sucotond USA coordinates non-confidential feasibility review for U.S. brands. The starting point is not a generic stock claim: it is the exact glutathione material, declared amount, serving, gummy system, analytical method, package and evidence plan.

No universal dose, absorption claim, shelf life, MOQ, lead time or finished-product result is promised on this page. Each is confirmed, where applicable, for the approved project.

Finished functional gummy bottles on the production lineSpecification-First Intake
IngredientExact form and supplier basis
Declared amountPer serving, not just per piece
Finished-product assayMethod and acceptance criterion
PackageMatched to stability assumptions
Commercial termsConfirmed after feasibility
Current service status: open for non-confidential custom-project review. The Guangzhou page confirms glutathione as an available product direction; this U.S. page adds the buyer specification, evidence and RFQ controls needed before a project commitment.
Quote-Ready Brief

Six decisions to settle before comparing manufacturers

“Glutathione gummy” is a product category, not a complete purchasing specification.

1. Ingredient identity

State the exact material name and form, supplier or acceptable alternatives, grade, component specification, lot documentation and any branded-ingredient rights.

2. Declared amount

Define the amount per serving, acceptable gummies per serving, label basis and piece-weight constraints. Do not compare quotes that use different serving designs.

3. Gummy matrix

Define pectin or gelatin direction, sweetener system, flavor, color, coating, dietary exclusions and the acceptable sensory range after the active is added.

4. Analytical release

Agree the analyte, specification, sample, method, unit, laboratory, acceptance criterion and disposition owner. A raw-material COA is not automatically a finished-product result.

5. Package and stability

Specify bottle or pouch, count, closure, liner or moisture-control assumptions, storage conditions, distribution route and the evidence expected for any labeled shelf-life date.

6. Commercial scope

Use the same volume, packaging, testing, document scope, delivery point and timing assumptions when comparing MOQ, unit cost and lead time.

Claims boundary: this page makes no disease, detoxification, skin-lightening, immune-performance, bioavailability or clinical-outcome claim. NIH notes that evidence for oral glutathione outcomes depends on the exact use and study context. Brand claims require exact-product evidence and qualified U.S. regulatory review.
Failure-Mode Review

Build the evidence plan around the ways a quote can stop being comparable

Material-name ambiguity

“Glutathione,” “reduced glutathione” and branded materials can carry different specification, sourcing and evidence implications. Lock the name and supplier basis before sample approval.

Serving-load mismatch

A low piece price can hide a different declared amount, gummy count or bottle count. Compare cost per declared serving and per delivered bottle, not price per gummy alone.

Sample-to-batch drift

The approved prototype must be linked to the commercial formula, component lots, process, package and acceptance criteria. Document every intentional difference.

Method and unit mismatch

A result cannot be interpreted without the sample identity, analyte, method, unit and specification. Define whether the release decision belongs to component, in-process or finished product.

Package assumption drift

Container, closure, fill count and moisture/oxygen controls belong in the stability scope. A shelf-life statement from another package is not product-specific evidence.

Unsupported marketing transfer

Supplier literature for one material or dosage form does not automatically validate a different gummy. Keep ingredient evidence, finished-product evidence and brand wording separate.

Evidence Chain

Connect the declared serving to an identified released batch

Material

Supplier, grade, lot, identity and component specification.

Formula

Approved quantities, serving, gummy matrix and package.

Sample

Version, attributes, tests, differences and approval limits.

Batch

Actual components, master/batch records and deviations.

Release

Applicable results, label/package checks and disposition.

Use the product specification checklist, sample-to-commercial transfer checklist and laboratory report checklist to record those controls.

Public Evidence

What authoritative sources support—and what they do not

FDA: specifications and scientifically valid methods

FDA's dietary-supplement CGMP guide describes component, in-process, finished-batch, packaging and label specifications. It also says tests or examinations used to determine whether specifications are met must be appropriate and scientifically valid. That supports a method-and-specification-first purchasing process; it does not approve this product or promise a result.

Read the FDA CGMP guide

NIH ODS: ingredient context is not a finished-product claim

NIH's Office of Dietary Supplements discusses glutathione within an evidence review and notes limits and uncertainty for oral supplementation in specific contexts. This page therefore avoids transferring general ingredient discussion into a promise about a custom gummy.

Review the NIH ODS evidence summary

Responsibility Map

Keep sales, manufacturing, brand and evidence roles distinct

Brooklyn project office

Sucotond USA coordinates buyer requirements, quotation inputs, document requests, status and delivery planning.

Guangzhou production facility

Sucotond (Guangzhou) Health Biotechnology Co., Ltd. handles product-specific feasibility, development, manufacturing and batch controls.

Brand / responsible firm

The brand approves the specification, sample, label, claims, evidence expectations and commercial terms with qualified review.

Laboratory and document owners

Each report must be matched to the correct material, sample or batch, and disclosure rights remain document-specific.

Buyer FAQ

Glutathione gummy sourcing questions

Do you offer private label glutathione gummies?

Glutathione is an available project direction, but the commercial formula, ingredient, amount, sensory system, testing, package, MOQ, timing and price require project-specific feasibility and written confirmation.

Can the raw-material COA release the finished gummy?

Not by itself. Component evidence and finished-batch evidence answer different questions. The project should define the finished-product specifications selected for release and the appropriate tests or examinations used to support them.

What should I send for an initial review?

Send the target U.S. market, exact ingredient or acceptable forms, amount per serving, pieces per serving, gummy base, flavor direction, package, testing and document expectations, volume stage, delivery point and timing. Keep the first message non-confidential.

Non-Confidential Project Intake

Request a glutathione gummy feasibility map

Send the ingredient, serving, gummy system, package, testing, evidence, market, volume and timing assumptions that a supplier quote should use.

U.S. Office
7624 17th Ave
Brooklyn, NY 11214
Business Hours
Monday–Friday, 9:00–18:00 ET

Do not submit confidential formula details before an NDA is in place. By submitting, you agree that Sucotond USA may use these details to evaluate and respond to the inquiry. Privacy notice.

Thanks — your brief was received.
The project inputs are ready for internal review.